ovarian function
Conditions
Interventions
Sponsors
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
Female
Age
40 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1) Between the ages of 40 and 50, perimenopausal; 2) Women with menopause or menstrual disorders for 2 months (or more) and FSH>25U/L; 3) Those who have used medication have completed the washout period requirements; 4) Voluntarily participate in this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Artificial menopause (bilateral ovariectomy/hysterectomy/radiation chemotherapy destroying ovarian function, etc.), gynecological organic lesions (maximum diameter of uterine fibroids>2cm), patients with severe breast hyperplasia, menopausal individuals with vaginal color ultrasound monitoring of endometrium (double layer) = 0.5cm, endometriosis, adenomyosis, ovarian cysts (maximum diameter = 3cm or simple ovarian cysts), endometrial polyps, abnormal uterine bleeding Malignant tumor patients; 2) Complicated with cardiovascular, cerebrovascular, liver, kidney, hematopoietic system, diabetes and other serious primary diseases; 3) Previously diagnosed with hyperthyroidism, hypothyroidism, or hyperlipidemia, and still requiring medication treatment; 4) Allergic constitution (people who are allergic to two or more foods/drugs); 5) Patients with trichomonas, fungal or bacterial vaginal infections, urinary tract infections, and other diseases; 6) Patients who have used traditional Chinese medicine/Western medicine with similar effects to the research product and have not reached the corresponding washout period specified in the protocol; 7) Individuals who are currently or have participated in other clinical studies within the past 3 months; 8) Vulnerable groups, including critically ill patients, mentally ill individuals, cognitive impairment individuals, minors, pregnant women, illiterate individuals, etc; 9) Researchers believe that there are other situations where it is not suitable to participate in clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LH;FSH;E2;AMH; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improved Kupperman Scale Scoring;Ovarian ultrasound examination;Structure of fecal microbiota; | — |
Countries
China
Contacts
Public ContactChen Shujie
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Outcome results
None listed